Figure - PMC

Skip to main content

An official website of the United States government

Here's how you know

Here's how you know

Official websites use .gov
A .gov website belongs to an official government organization in the United States.

Secure .gov websites use HTTPS
A lock ( ) or https:// means you've safely connected to the .gov website. Share sensitive information only on official, secure websites.

View full-text article in PMC

. 2016 May 27;8(6):1064–1078. doi: 10.1080/19420862.2016.1193660

Search in PMC
Search in PubMed
View in NLM Catalog
Add to search

© Taylor & Francis Group, LLC

PMC Copyright notice

Figure 7. — Single Species Allometric Scaling of CL for mAbs. Allometric Scaling for mAbs in NHP (15/27mAbs), WT mice (11/27mAbs), and hFcRn Tg32 hemizygous and homozygous mice (15/27 mAbs), comparing a standard scaling exponent of 0.75 (top row) to an empirically derived best fit exponent (middle row) per animal model. Results are plotted against a line of unity (solid black line) ± 2-fold error (dotted gray lines) where accuracy is described as the percentage (%) of mAbs predicted within 2-fold of the line of unity. Symbols: •, definitive linear CL values; ▴, apparent linear CL in rodent or NHP; ▪, apparent linear CL in human; ♦ apparent linear CL in rodent or NHP and human. •, training data set. , test set, marketed therapeutic mAbs.

Inline graphic — Single Species Allometric Scaling of CL for mAbs. Allometric Scaling for mAbs in NHP (15/27mAbs), WT mice (11/27mAbs), and hFcRn Tg32 hemizygous and homozygous mice (15/27 mAbs), comparing a standard scaling exponent of 0.75 (top row) to an empirically derived best fit exponent (middle row) per animal model. Results are plotted against a line of unity (solid black line) ± 2-fold error (dotted gray lines) where accuracy is described as the percentage (%) of mAbs predicted within 2-fold of the line of unity. Symbols: •, definitive linear CL values; ▴, apparent linear CL in rodent or NHP; ▪, apparent linear CL in human; ♦ apparent linear CL in rodent or NHP and human. •, training data set. , test set, marketed therapeutic mAbs.